Lycia Therapeutics (LYCA) closed at $31.77 on November 19, 2026, up 1.3% from the previous close, on volume of 273,790 shares (30-day average 432,589).
Data as of November 19, 2026.
Analysts Are Bullish on Top Healthcare Stocks: Medtronic (MDT), Lycia Therapeutics, Inc. (LYCA)
TipRanks (Tue, 17-Nov 5:10 AM ET)
Lycia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
Globe Newswire (Wed, 11-Nov 7:30 AM ET)
Globe Newswire (Mon, 26-Oct 4:12 PM ET)
Lycia Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory and allergic diseases.
Lycia Therapeutics trades on the NASDAQ stock market under the symbol LYCA.
As of November 19, 2026, LYCA stock price climbed to $31.77 with 273,790 million shares trading.
LYCA has a market cap of $1.66 billion. This is considered a Small Cap stock.
The top ETF exchange traded funds that LYCA belongs to (by Net Assets): VTI, VXF.
LYCA support price is $29.13 and resistance is $33.57 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LYCA shares will trade within this expected range on the day.